Patent · US Active

Anti-EGFR antibodies and antibody drug conjugates

US9493568B2 · kind B2 · utility

9Cited by
9References
22Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 20, 2015
Grant dateNov 15, 2016
Priority date
Expiry dateMar 20, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.